The earnings call highlighted significant progress in advancing pivotal clinical trials and maintaining a strong financial position, with ongoing collaborations and upcoming strategic events. However, ongoing arbitration and a decrease in cash reserves posed challenges.

Company Guidance

During Cellectis' Second Quarter 2025 Earnings Call, the company provided guidance on several key metrics. They announced the completion of end-of-Phase I discussions with the FDA and EMA for lasme-cel, UCART22, in relapsed or refractory acute lymphoblastic leukemia, and their preparation to initiate a pivotal Phase II trial in the second half of 2025. Additionally, the NatHaLi-01 study on UCART20x22 is progressing, with Phase I data anticipated by late 2025. Cellectis is advancing three cell and gene therapy programs under their partnership with AstraZeneca. Financially, the company reported cash, cash equivalents, and fixed-term deposits of $230 million as of June 30, 2025, which are expected to fund operations into the second half of 2027. They are also involved in arbitration with Servier, with a decision expected by December 15, 2025. The company will provide further insights and data during their Investor R&D Day on October 16, 2025.

Initiation of Pivotal Phase II Trial for lasme-cel

Cellectis is preparing to initiate the pivotal Phase II trial for lasme-cel (UCART22) in relapsed or refractory acute lymphoblastic leukemia in the second half of 2025, following successful end of Phase I discussions with the FDA and EMA.

Ongoing R&D Partnership with AstraZeneca

Research and development activities continue under the collaboration with AstraZeneca, focusing on three cell and gene therapy programs, including CAR-T for hematological malignancies, CAR-T for solid tumors, and in vivo gene therapy for a genetic disorder.

Strong Financial Position

Cellectis' cash, cash equivalents, and fixed-term deposits as of June 30, 2025, amount to $230 million, sufficient to fund operations into H2 2027.

Upcoming Investor R&D Day

Cellectis will host an Investor R&D Day on October 16, 2025, to present Phase I data and late-stage development strategy for lasme-cel.

Cellectis SA (FR:ALCLS) Earnings, Revenues Date & History

The upcoming earnings date is based on a company’s previous reporting, and may be updated when the actual date is announced

Daily Earnings Calendar >

FR:ALCLS Earnings History

Report Date	Fiscal Quarter	Forecast / EPS	Last Year's EPS	EPS YoY Change	Slides	Play Transcript
Mar 11, 2026	2025 (Q4)	-0.27 / -	-0.156	―	―	―
Nov 07, 2025	2025 (Q3)	-0.20 / <0.01	-0.211	104.27% (+0.22)	―	―
Aug 04, 2025	2025 (Q2)	-0.19 / -0.21	-0.256	18.75% (+0.05)	―
May 12, 2025	2025 (Q1)	-0.14 / -0.16	0.074	-317.57% (-0.23)	―	―
Mar 13, 2025	2024 (Q4)	-0.17 / -0.16	-0.599	73.96% (+0.44)	―
Nov 04, 2024	2024 (Q3)	-0.22 / -0.21	-0.29	27.24% (+0.08)	―
Aug 06, 2024	2024 (Q2)	-0.26 / -0.26	-0.172	-48.84% (-0.08)	―	―
May 28, 2024	2024 (Q1)	-0.31 / 0.07	-0.527	114.04% (+0.60)	―
Mar 11, 2024	2023 (Q4)	-0.26 / -0.07	-0.558	86.56% (+0.48)	―	―
Nov 06, 2023	2023 (Q3)	-0.39 / -0.29	-0.637	54.47% (+0.35)	―

The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.

Beat

Missed

FR:ALCLS Earnings-Related Price Changes

Report Date	Price 1 Day Before	Price 1 Day After	Percentage Change
Nov 07, 2025	€2.86	€3.21	+12.24%
Aug 04, 2025	€2.75	€2.33	-15.12%
May 12, 2025	€1.35	€1.33	-1.33%
Mar 13, 2025	€1.25	€1.22	-1.92%

Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.

FAQ

When does Cellectis SA (FR:ALCLS) report earnings?

Cellectis SA (FR:ALCLS) is schdueled to report earning on Mar 11, 2026, TBA (Confirmed).

What is Cellectis SA (FR:ALCLS) earnings time?

Cellectis SA (FR:ALCLS) earnings time is at Mar 11, 2026, TBA (Confirmed).

Where can I see when companies are reporting earnings?

You can see which companies are reporting today on our designated earnings calendar.

What companies are reporting earnings today?

You can see a list of the companies which are reporting today on TipRanks earnings calendar.

What is the P/E ratio of Cellectis SA stock?

The P/E ratio of Cellectis SA is N/A.

What is FR:ALCLS EPS forecast?

FR:ALCLS EPS forecast for the fiscal quarter 2025 (Q4) is -0.27.